BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gamble MC, Katsuki F, Mccoy JG, Strecker RE, Mckenna JT. The dual orexinergic receptor antagonist DORA-22 improves the sleep disruption and memory impairment produced by a rodent insomnia model. Sleep 2019. [DOI: 10.1093/sleep/zsz241] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Van Someren EJW. Brain mechanisms of insomnia: new perspectives on causes and consequences. Physiol Rev 2021;101:995-1046. [PMID: 32790576 DOI: 10.1152/physrev.00046.2019] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
2 Wang Q, Cao F, Wu Y. Orexinergic System in Neurodegenerative Diseases. Front Aging Neurosci 2021;13:713201. [PMID: 34483883 DOI: 10.3389/fnagi.2021.713201] [Reference Citation Analysis]
3 Roch C, Bergamini G, Steiner MA, Clozel M. Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia. Psychopharmacology (Berl) 2021;238:2693-708. [PMID: 34415378 DOI: 10.1007/s00213-021-05954-0] [Reference Citation Analysis]